#$ocat

What is Astellas Pharma, the purchaser of Ocata?

Photo from freestockphotos

Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology).

This has stirred a lot of strong feelings amongst investors in Ocata.

I’ve also been wondering what exactly is Astellas Pharma?

Astellas is a giantcompared to Ocata with reportedly $11 billion USD in revenue and $1.3 billion in profit just in the year 2013 alone. While Ocata…

Tale of 7 stem cell stock woes: how low can they go?

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road.

Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those companies fare financially is not just of interest to investors, but also should be on the radar screen of…

Monday morning musings: stem cell stocks, ISSCR, grants, CRISPR, New Book, & more

What’s on your mind on this Monday morning? Are you caffeinated enough yet? Depending on where you live it may even be time for dinner, bed, or already early Tuesday.

Here’s some musings…

To get safe and effective stem cell treatments to patients in a responsible, compliant manner you need commercial efforts and that in almost all cases means biotechs.

Doing this blog for 5+ years has made it…